p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.

CONCLUSIONS: p53MVA was well tolerated, but gemcitabine without steroid pre-treatment was intolerable in some patients. However, elevated p53-reactive CD4+ and CD8+T cell responses post therapy correlated with longer PFS. Therefore, if responses to p53MVA could be enhanced with alternative agents, superior clinical responses may be achievable.
PMID: 29301826 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 4, 2018 Category: Cancer & Oncology Authors: Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, Kaltcheva TI, Leong L, Morgan R, Chung V, Tinsley R, Eng M, Wilczynski SP, Ellenhorn JDI, Diamond DJ, Cristea M Tags: Clin Cancer Res Source Type: research